An observational study in Renal Cell Carcinoma, sponsored by Pfizer. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-18.
Sponsored by Pfizer · Observational
Non-interventional study. Data obtained by patient chart reviews.
Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in Denmark from 2006-2010 Safety, prognostic factors, predictive factors and co-morbidity assessed by Charlson Comorbidity Index.
The following drugs will be evaluated: Sunitinib, Sorafenib, Temsirolimus, Everolimus, Aldesleukin, Interferon-alfa-2b.
No sampling. All eligible patients will be included.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 1,073 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
All Danish patients diagnosed with metastatic renal cell carcinoma referred to the involved centers.
Metastatic renal cell carcinoma
Exclusion Criteria:
None
Outcomes Research Study
Other: Non-interventional
Non-interventional (retrospective chart reviews)
Overall survival from initiation of first systemic anticancer therapy
Time frame: 8 months
Progression free survival from initiation of each systemic anticancer therapy separately
Time frame: 8 months
Time to treatment failure from initiation of each systemic anticancer therapy separately
Time frame: 8 months
Prognostic factors at baseline associated with efficacy (PFS) of each systemic anticancer therapy and overall survival
Time frame: 8 months
Serious Adverse Events: Defined as AEs leading to dose adjustment, treatment interruption/ cessation or death.
Time frame: 8 months
Predictive factors
Time frame: 8 months
Co-morbidity assessed by Charlson Comorbidity Index
Time frame: 8 months
Combined PFS and OS on sequential treatment
Time frame: 8 months
Assessment of first line immunotherapy´s effect on second line targeted therapy
Time frame: 8 months
Assessment of prognostic factors and overall survival for patients not receiving systemic therapy
Time frame: 8 months
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer